Newton Charles W. 4

What Happened Charles W. Newton, a director of Keros Therapeutics, sold 550 shares in open-market transactions on June 11, 2026. The filing reports a weighted-average sale price of $10.04 per share for total gross proceeds of $5,522. The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan adopted March 12, 2026.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-15 (timely filed within the two-business-day window).
• Transaction type/code: Sale (S) — open market/private sale reported as multiple trades.
• Shares sold: 550; weighted-average price: $10.04; gross proceeds: $5,522.
• Price range: shares were sold in multiple transactions at prices ranging from $9.83 to $10.16. The reporting person offers to provide a breakdown of the number of shares sold at each price on request (see footnote).
• Shares owned after transaction: Not specified in the filing.
• Notable footnote: Transactions were made under a Rule 10b5-1 plan (adopted March 12, 2026); weighted-average price reflects multiple trade prices (footnotes F1 and F2).

Context This sale was executed under a prearranged 10b5-1 plan, which commonly governs routine insider sales and does not, by itself, indicate the director's current view of the company. The dollar amount is small relative to typical insider trades; purchases are generally considered more informative than routine sales.